CLSI M100-2020

VIP免费

史蒂文 2024-12-03 49 13.32MB 332 页 18星币

侵权投诉

M100

Performance Standards for Antimicrobial

Susceptibility Testing

This document includes updated tables for the Clinical and

Laboratory Standards Institute antimicrobial susceptibility testing

standards M02, M07, and M11.

A CLSI supplement for global application.

30th Edition

CLSI eCLIPSE - Dewanand Mahto - BD - 01/29/2020. Unauthorized duplication or network sharing is not allowed.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-prot membership organization that brings

together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a

common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory

standards and guidelines that help laboratories fulll their responsibilities with eﬃciency, eﬀectiveness, and global

applicability.

Consensus Process

Consensus—the substantial agreement by materially aﬀected, competent, and interested parties—is core to the

development of all CLSI documents. It does not always connote unanimous agreement but does mean that the

participants in the development of a consensus document have considered and resolved all relevant objections

and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modication to keep pace with advances in technologies,

procedures, methods, and protocols aﬀecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants

in the reviewing and commenting process. At the end of each comment period, the committee that developed

the document is obligated to review all comments, respond in writing to all substantive comments, and revise the

draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on

any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for

appeal, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on le at CLSI and are

available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get

involved in the revision process? Or maybe you see a need to develop a new document for an emerging

technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents

to improve the standards that aﬀect your own work, you will play an active role in improving public health across

the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

950 West Valley Road, Suite 2500

Wayne, PA 19087 USA

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

CLSI eCLIPSE - Dewanand Mahto - BD - 01/29/2020. Unauthorized duplication or network sharing is not allowed.

M100, 29th ed.

January 2019

Replaces M100, 28th ed.

Performance Standards for Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD

Jean B. Patel, PhD, D(ABMM)

April M. Bobenchik, PhD, D(ABMM)

Shelley Campeau, PhD, D(ABMM)

Sharon K. Cullen, BS, RAC

Marcelo F. Galas

Howard Gold, MD, FIDSA

Romney M. Humphries, PhD, D(ABMM)

Thomas J. Kirn, Jr., MD, PhD

James S. Lewis II, PharmD, FIDSA

Brandi Limbago, PhD

Amy J. Mathers, MD, D(ABMM)

Tony Mazzulli, MD, FACP, FRCP(C)

Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA

Michael Satlin, MD, MS

Audrey N. Schuetz, MD, MPH, D(ABMM)

Jana M. Swenson, MMSc

Pranita D. Tamma, MD, MHS

Abstract

The data in the tables are valid only if the methodologies in CLSI documents M02,1 M07,2 and M113 are followed. These

standards contain information about disk diffusion (M021) and dilution (M072 and M113) test procedures for aerobic and

anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill

patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal

conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in

M100 represent the most current information for drug selection, interpretation, and quality control using the procedures

standardized in M02,1 M07,2 and M11.3 Users should replace previously published tables with these new tables. Changes in the

tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 29th ed.

CLSI supplement M100 (ISBN 978-1-68440-032-4 [Print]; ISBN 978-1-68440-033-1 [Electronic]). Clinical and Laboratory

Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2019.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through

two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any

given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or

guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in

the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to

become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail:

customerservice@clsi.org; Website: www.clsi.org.

M100, 30th ed.

January 2020

Replaces M100, 29th ed.

Performance Standards for Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD

James S. Lewis II, PharmD, FIDSA

April M. Bobenchik, PhD, D(ABMM)

Shelley Campeau, PhD, D(ABMM)

Sharon K. Cullen, BS, RAC

Marcelo F. Galas

Howard Gold, MD, FIDSA

Romney M. Humphries, PhD, D(ABMM)

Thomas J. Kirn, Jr., MD, PhD

Brandi Limbago, PhD

Amy J. Mathers, MD, D(ABMM)

Tony Mazzulli, MD, FACP, FRCP(C)

Michael Satlin, MD, MS

Audrey N. Schuetz, MD, MPH, D(ABMM)

Patricia J. Simner, PhD, D(ABMM)

Pranita D. Tamma, MD, MHS

Abstract

The data in the tables are valid only if the methodologies in CLSI documents M02,1 M07,2 and M113 are followed. These

standards contain information about disk diffusion (M021) and dilution (M072 and M113) test procedures for aerobic and

anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill

patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal

conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in

M100 represent the most current information for drug selection, interpretation, and quality control using the procedures

standardized in M02,1 M07,2 and M11.3 Users should replace previously published tables with these new tables. Changes in the

tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed.

CLSI supplement M100 (ISBN 978-1-68440-066-9 [Print]; ISBN 978-1-68440-067-6 [Electronic]). Clinical and Laboratory

Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2020.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through

two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any

given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or

guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in

the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to

become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail:

customerservice@clsi.org; Website: www.clsi.org.

CLSI eCLIPSE - Dewanand Mahto - BD - 01/29/2020. Unauthorized duplication or network sharing is not allowed.

文档加载中……请稍候！
如果长时间未打开，您也可以点击刷新试试。

下载文档到电脑，查找使用更方便

亲，本站95%以上的标准规范都面向会员免费，办理VIP会员下载更省钱，平均每篇不到2元

立即下载 VIP免费下载

摘要：

CLSI M100-2020 是由美国临床和实验室标准协会发布的第30版抗菌药物敏感性试验执行标准，是全球临床微生物实验室进行药敏试验、结果判读和质量控制的核心权威指南。该文档系统更新了肠杆菌科、铜绿假单胞菌、金黄色葡萄球菌等关键病原体的折点标准、筛查试验方法及报告规则，并新增了对新型抗菌药物（如头孢他啶-阿维巴坦）的解读建议。实验室遵循CLSI M100-2020可确保药敏结果与国际最新循证医学依据保持一致，有效指导抗菌药物的合理选用，降低耐药性风险。该标准适用于医院微生物室、临床医生、感染控

展开>> 收起<<

CLSI M100-2020.pdf

共332页,预览4页

还剩页未读，继续阅读

声明：本文档系会员上传，若文档所含内容侵犯了您的版权或隐私，请立即通知，我们立即给予侵权申诉删除！

CLSI M100-2020

相关推荐

开通VIP享超值会员特权

相关内容

热门标签

举报选择: